Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals Inc (ATNM) Implied Volatility Current
ATNM's 30 day implied volatility is 0.01%, with an IV Rank of 2.98%. This is a low IV Rank versus the past year, meaning Actinium Pharmaceuticals Inc options are relatively cheap and currently favor buyers. ATNM's 30 day historical volatility sits at 126.11%, which means implied volatility is running 126.10 points below historical volatility, as of Nov 18, 2026.
Read more
Tracking ATNM implied volatility helps you spot when Actinium Pharmaceuticals Inc options are historically cheap or expensive, and where the best trades are hiding. When ATNM IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor ATNM implied volatility current levels in real time and filter for high probability trades.
Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking ATNM IV rank helps you see whether ATNM's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities.
Implied Volatility
IV is subdued. Premiums are cheap, favoring buyers.
As of Nov 18, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →